Glucagon like-peptide-1 receptor is covalently modified by endogenous mono-ADP-ribosyltransferase

Our previous study revealed a mono-ADP-ribosyltransferase mediated in vitro mono-ADP-ribosylation of IC₃ peptide, a peptide with sequence corresponded to third intracellular loop of glucagon like-peptide-1 (GLP-1) receptor. Furthermore, Arg³⁴⁸ was shown to be modified amino acid residue although its mutation did not eliminate mono-ADP-ribosylation completely. In order to further study the signaling mechanisms of GLP-1 receptor, we took on lease a possibility that an alternative site of enzymatic modification exist so mono-ADP-ribosylation of Cys³⁴¹ was hypothesized. The results confirmed both Arg³⁴⁸ and Cys³⁴¹ as a site of mono-ADP-ribosylation where Arg³⁴⁸ is modified predominantly. Sum of mono-ADP-ribosylation rate of both single IC₃ mutants coincided with IC₃ rate. What is in vivo role of Cys³⁴¹ mono-ADP-ribosylation is entirely speculative but our study represents an important step toward a complete understanding of signaling via GLP-1 receptor.